Facioscapulohumeral muscular dystrophy is a genetic muscle disorder that gradually weakens and shrinks muscles throughout the body, most notably affecting the face, shoulders, and upper arms, though it can eventually spread to nearly any muscle group. This condition varies tremendously from person to person—some individuals remain only mildly affected throughout their lives, while others experience more significant physical limitations.

Understanding the Global Impact of FSHD

Facioscapulohumeral muscular dystrophy, commonly shortened to FSHD, ranks as the third most common type of muscular dystrophy worldwide, following only Duchenne muscular dystrophy and myotonic dystrophy in frequency. While exact numbers remain uncertain, researchers estimate that FSHD affects approximately 1 in 8,000 to 1 in 20,000 individuals globally, translating to roughly 870,000 people worldwide living with this condition.^[1][4][5] The true prevalence may actually be higher than these estimates suggest, because many cases remain undiagnosed when symptoms are mild or individuals never develop noticeable signs of the disease.

This genetic disorder affects people across all racial and ethnic backgrounds, demonstrating no preference for any particular population. Unlike some forms of muscular dystrophy that predominantly affect one sex, FSHD strikes men, women, and children with relatively equal frequency.^[4][12] However, men often experience more pronounced symptoms compared to women with the condition. About 95 percent of affected individuals begin showing outward signs of muscle weakness by their second decade of life for men and third decade for women, though the actual onset of symptoms can vary dramatically.^[7]

The age when symptoms first appear provides important clues about disease severity. Most commonly, weakness begins during the teenage years or in early adulthood, typically between ages 15 and 30.^[2][6] Approximately 10 percent of individuals develop symptoms before age 10, a presentation known as early-onset or infantile FSHD.^[4] These early-onset cases tend to follow a more aggressive course, with greater muscle weakness and sometimes additional complications affecting hearing and vision. On the opposite end of the spectrum, milder cases may not become noticeable until much later in life, or symptoms may remain so subtle that affected individuals never seek medical evaluation.

The Genetic Origins of Muscle Weakness

FSHD is fundamentally a genetic condition passed down through families in what scientists call an autosomal dominant pattern, meaning a child needs to inherit only one altered gene from either parent to develop the disorder.^[3][12] Each child of an affected parent has a 50 percent chance of inheriting the genetic change and potentially developing FSHD. However, between 10 and 30 percent of cases arise from spontaneous mutations—new genetic changes that occur for the first time in an individual without any family history of the condition.^[12]

The disease stems from inappropriate activation of a gene called DUX4, which normally remains switched off in most cells throughout the body. This gene is typically only active in very early embryonic development and in reproductive tissue. In people with FSHD, genetic changes cause the DUX4 gene to become abnormally active in muscle cells, where it produces toxic proteins that damage and ultimately destroy muscle tissue.^[2][5] This toxic protein expression leads to the progressive muscle weakness and wasting that characterizes the condition.

The genetic mechanism involves a region of DNA on chromosome 4 called D4Z4, which consists of repeated segments of genetic material. In people without FSHD, this region contains between 11 and 100 repeated segments, and these segments are heavily methylated—a chemical modification that keeps genes in that region silenced.^[5] In FSHD, problems with this D4Z4 region lead to reduced methylation, allowing the DUX4 gene to escape normal controls and become active in muscle tissue.

Scientists have identified two types of FSHD based on the underlying genetic cause. FSHD type 1, accounting for about 95 percent of cases, occurs when the D4Z4 region becomes abnormally shortened, containing only 1 to 10 repeated segments instead of the normal 11 to 100.^[2][5] This contraction of the D4Z4 region disrupts normal gene silencing. FSHD type 2, representing the remaining 5 percent of cases, results from mutations in other genes, most commonly the SMCHD1 gene on chromosome 18, which normally helps maintain methylation of the D4Z4 region.^[5][7] Despite different genetic origins, both types produce identical symptoms and cannot be distinguished clinically.

Who Is at Risk for Developing FSHD

The primary risk factor for developing FSHD is having a parent with the condition. Because the disorder follows an autosomal dominant inheritance pattern, children of affected individuals face a 50 percent chance of inheriting the altered gene. However, inheriting the genetic change does not guarantee that symptoms will develop, and even within the same family, the severity and age of onset can vary dramatically.^[6]

The number of D4Z4 repeated segments plays a crucial role in determining disease severity and when symptoms will appear. Individuals with fewer repeats—between 1 and 3 copies—are most likely to develop symptoms during childhood and typically experience more severe disease progression. Those with 4 to 7 repeats often develop symptoms during their teenage years or later, while individuals with 8 to 10 repeats tend not to show signs until adulthood, if at all.^[19] This correlation between genetic changes and disease severity helps explain why FSHD affects people so differently.

Male sex appears to be a risk factor for more pronounced symptoms. While men and women inherit FSHD equally, men often experience more severe muscle weakness and earlier symptom onset compared to women with the same genetic changes.^[1][12] The reasons for this difference remain unclear but may relate to hormonal or other biological factors that provide some protective effect in women.

Recognizing the Signs and Symptoms

The name facioscapulohumeral muscular dystrophy directly describes the areas of the body typically affected first. “Facio” refers to facial muscles, “scapulo” relates to the shoulder blade area, and “humeral” indicates the upper arm. In approximately 90 percent of people with FSHD, weakness begins in these characteristic areas, though the disease eventually spreads to affect other muscle groups.^[1]

Facial muscle weakness often represents the earliest sign, though it can be so subtle that individuals and even physicians fail to notice it initially. People with FSHD lose the ability to fully close their eyes during sleep, which can lead to dry eyes and eye irritation upon waking. They cannot purse their lips properly, making it impossible to whistle or drink through a straw. Smiling becomes difficult, and facial expressions may appear limited or flat.^[2][5] Some individuals develop difficulty pronouncing certain words clearly due to weakened muscles around the mouth and cheeks.

Shoulder and upper arm weakness typically becomes the most noticeable and functionally limiting symptom. The muscles that normally hold the shoulder blades flat against the back become weak, causing the shoulder blades to protrude outward and upward in a distinctive pattern called scapular winging.^[2][5] This creates a wing-like appearance when viewed from behind. Weakness in the shoulders and upper arms makes it progressively harder to raise the arms above shoulder height, reach overhead to get items from high shelves, lift objects, or throw a ball. These limitations significantly impact daily activities like combing hair, washing, dressing, or placing items in overhead storage.

As FSHD progresses, weakness spreads to involve the muscles of the lower legs, abdominal wall, hips, and trunk. Weakness in the muscles that lift the front of the foot leads to a condition called foot drop, where the toes drag during walking, increasing the risk of tripping and falling.^[2][5] Abdominal muscle weakness causes the belly to protrude, and weakness in back muscles can lead to an exaggerated inward curve of the lower back called lordosis. Some individuals develop sideways curvature of the spine known as scoliosis. Hip and pelvic weakness makes climbing stairs, rising from chairs, and walking long distances increasingly challenging.

A distinctive feature of FSHD is that muscle weakness typically affects the two sides of the body unequally. One shoulder or arm may be significantly weaker than the other, or weakness may be present on one side while the opposite side remains relatively strong. This asymmetric pattern helps distinguish FSHD from other forms of muscular dystrophy.^[5][7]

Beyond muscle weakness, many people with FSHD experience debilitating chronic fatigue that affects their ability to work, socialize, and maintain daily routines. More than 70 percent report significant pain, which can be severe enough to require specialized pain management.^[2][4] Some individuals also experience high-frequency hearing loss and abnormalities in the blood vessels at the back of the eye, though these complications often remain unnoticed without specific medical testing.^[3][5] Rarely, FSHD can affect the heart muscle or muscles involved in breathing, though these complications are uncommon.

About 20 percent of individuals with FSHD eventually require wheelchair assistance, typically after age 50, though this varies considerably depending on disease severity.^[2][4] Despite progressive muscle weakness, most people with FSHD maintain a normal lifespan.

Strategies for Prevention and Early Detection

Because FSHD results from inherited or spontaneous genetic changes present from birth, there is currently no way to prevent the condition from developing in individuals who carry the altered genes. However, families with a history of FSHD have several options for understanding their risk and making informed reproductive decisions.

Genetic testing provides definitive diagnosis and can identify whether family members have inherited the genetic changes associated with FSHD, even before symptoms appear. For families planning to have children, genetic counseling offers valuable information about inheritance patterns, testing options, and reproductive choices. Prenatal testing through procedures like amniocentesis or chorionic villus sampling can determine whether a developing fetus has inherited the FSHD-associated genetic changes.^[7] For couples using in vitro fertilization, preimplantation genetic diagnosis allows testing of embryos before implantation, enabling selection of embryos without the genetic changes.

While prevention of FSHD itself is not possible, early diagnosis enables individuals to access appropriate medical care, physical therapy, and supportive services that can improve quality of life and potentially slow functional decline. Regular monitoring allows healthcare providers to detect and address complications such as hearing loss, vision problems, or spine curvature before they cause significant problems.

For individuals already diagnosed with FSHD, certain lifestyle modifications may help maintain function and overall health. Staying physically active through appropriate exercise programs designed with guidance from physical therapists can help preserve muscle strength and flexibility without causing harm. Avoiding prolonged bed rest or inactivity is important, as muscle disuse can accelerate weakness.^[12] Maintaining a healthy weight reduces stress on weakened muscles and joints. Some individuals find that using assistive devices early, such as braces for foot drop or supportive equipment for daily activities, helps them remain active and independent longer.

How FSHD Changes Normal Body Function

Understanding how FSHD disrupts normal muscle function requires examining changes at both the molecular and tissue levels. In healthy individuals, the DUX4 gene remains tightly silenced in muscle tissue through epigenetic mechanisms—chemical modifications to DNA, particularly methylation, that prevent genes from being read and translated into proteins. The D4Z4 region on chromosome 4 normally contains enough repeated segments to maintain heavy methylation, keeping the DUX4 gene switched off throughout life except in very early development.^[5]

In FSHD, the contraction of D4Z4 repeats (in type 1) or mutations in genes that maintain methylation (in type 2) lead to reduced methylation of this region. This loss of methylation allows the DUX4 gene to escape normal repression and become sporadically active in muscle cells. When active, DUX4 produces a transcription factor protein—a molecule that controls the activity of many other genes. The DUX4 protein is highly toxic to muscle cells, triggering a cascade of harmful effects.^[14]

The DUX4 protein activates genes that are normally only expressed in early embryonic development and have no place in mature muscle tissue. This inappropriate gene activation disrupts normal muscle cell function and triggers pathways leading to cell death. The DUX4 protein also activates downstream genes such as PITX1, which further contributes to muscle damage.^[14] Over time, as muscle cells die, they are replaced by fat and fibrous tissue rather than being regenerated as functional muscle, leading to progressive weakness and atrophy.

When examined under a microscope, muscle tissue from people with FSHD shows characteristic changes. Muscle fibers vary greatly in size, with some appearing abnormally small and others enlarged. Dead and dying muscle cells appear alongside areas where muscle has been replaced by fat and connective tissue. Inflammatory cells may be present, though FSHD is primarily a degenerative rather than inflammatory condition.^[6]

The pattern of muscle involvement in FSHD follows a characteristic but puzzling sequence. Certain muscles are affected early and severely while others remain relatively spared even in advanced disease. Facial muscles, particularly those around the eyes and mouth, are among the first affected. In the shoulder region, muscles that stabilize the shoulder blade become weak while the deltoid muscle that caps the shoulder often remains strong, creating the characteristic winging appearance. In the arms, the biceps and triceps weaken while forearm muscles may be less affected. This selective vulnerability of specific muscles remains incompletely understood but likely relates to differences in how individual muscles respond to DUX4 toxicity.^[6]

In some individuals with FSHD, abnormalities develop in the blood vessels at the back of the eye, a condition called retinal telangiectasia. In severe cases, this can progress to a condition called Coats disease, where abnormal vessel growth and leakage can affect vision. The mechanisms linking DUX4 activity in muscle to blood vessel changes in the eye remain unclear.^[6] Similarly, about 50 percent of people with FSHD have subclinical high-frequency hearing loss, suggesting that DUX4 toxicity may affect tissues beyond skeletal muscle.^[3]